药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Istiratumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Istiratumab.
Mecasermin
Evinacumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Evinacumab.
Mecasermin
Sofituzumab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sofituzumab vedotin.
Mecasermin
Valanafusp alfa
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Valanafusp alfa.
Mecasermin
Gedivumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Gedivumab.
Mecasermin
Nemolizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Nemolizumab.
Mecasermin
Mitazalimab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Mitazalimab.
Mecasermin
Suvratoxumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Suvratoxumab.
Mecasermin
Asunercept
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Asunercept.
Mecasermin
Ponezumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ponezumab.
Mecasermin
Zolbetuximab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Zolbetuximab.
Mecasermin
Utomilumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Utomilumab.
Mecasermin
Telisotuzumab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Telisotuzumab vedotin.
Mecasermin
Tigatuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tigatuzumab.
Mecasermin
Tezepelumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tezepelumab.
Mecasermin
Frovocimab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Frovocimab.
Mecasermin
Abrilumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Abrilumab.
Mecasermin
Ipafricept
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ipafricept.
Mecasermin
Tafasitamab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tafasitamab.
Mecasermin
Apomab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Apomab.